Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSKA NASDAQ:LNTH NASDAQ:MYGN NASDAQ:NTLA NASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSKAHeska$119.99$119.09$57.83▼$120.03$1.31B1.58241,932 shsN/ALNTHLantheus$50.41-2.2%$60.91$47.25▼$118.21$3.51B0.151.11 million shs2.28 million shsMYGNMyriad Genetics$7.77+1.2%$5.78$3.76▼$28.15$714.58M1.931.40 million shs2.72 million shsNTLAIntellia Therapeutics$15.59-3.2%$11.84$5.90▼$22.70$1.73B2.284.81 million shs15.25 million shsQDELQuidelOrtho$28.78-3.2%$26.78$22.05▼$49.45$2.02B0.141.21 million shs1.68 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSKAHeska0.00%0.00%0.00%0.00%0.00%LNTHLantheus-2.23%-4.78%-10.21%-36.34%-53.38%MYGNMyriad Genetics+1.17%+7.32%+40.51%+57.93%-72.71%NTLAIntellia Therapeutics-3.23%+36.51%+52.69%+69.46%-30.77%QDELQuidelOrtho-3.23%+0.74%+9.26%+2.68%-37.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSKAHeska$119.99$119.09$57.83▼$120.03$1.31B1.58241,932 shsN/ALNTHLantheus$50.41-2.2%$60.91$47.25▼$118.21$3.51B0.151.11 million shs2.28 million shsMYGNMyriad Genetics$7.77+1.2%$5.78$3.76▼$28.15$714.58M1.931.40 million shs2.72 million shsNTLAIntellia Therapeutics$15.59-3.2%$11.84$5.90▼$22.70$1.73B2.284.81 million shs15.25 million shsQDELQuidelOrtho$28.78-3.2%$26.78$22.05▼$49.45$2.02B0.141.21 million shs1.68 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSKAHeska0.00%0.00%0.00%0.00%0.00%LNTHLantheus-2.23%-4.78%-10.21%-36.34%-53.38%MYGNMyriad Genetics+1.17%+7.32%+40.51%+57.93%-72.71%NTLAIntellia Therapeutics-3.23%+36.51%+52.69%+69.46%-30.77%QDELQuidelOrtho-3.23%+0.74%+9.26%+2.68%-37.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSKAHeska 0.00N/AN/AN/ALNTHLantheus 2.71Moderate Buy$85.5069.61% UpsideMYGNMyriad Genetics 2.21Hold$12.4560.29% UpsideNTLAIntellia Therapeutics 2.53Moderate Buy$27.3975.68% UpsideQDELQuidelOrtho 2.33Hold$39.2036.21% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, QDEL, HSKA, LNTH, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025NTLAIntellia TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform9/19/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.009/16/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$109.00 ➝ $84.009/15/2025LNTHLantheusTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$95.00 ➝ $80.008/13/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/11/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $60.008/8/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$50.00 ➝ $45.008/8/2025NTLAIntellia TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $21.008/8/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.008/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$112.00 ➝ $73.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSKAHeska$257.31M5.09$1.69 per share70.99$39.00 per share3.08LNTHLantheus$1.53B2.23$6.93 per share7.27$15.65 per share3.22MYGNMyriad Genetics$837.60M0.86$1.01 per share7.69$7.70 per share1.01NTLAIntellia Therapeutics$57.88M28.91N/AN/A$8.56 per share1.82QDELQuidelOrtho$2.78B0.70$34.67 per share0.83$44.38 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSKAHeska-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/ALNTHLantheus$312.44M$3.7613.417.99N/A17.82%34.06%19.10%11/5/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)QDELQuidelOrtho-$2.05B-$6.54N/A8.97N/A-16.10%5.29%2.43%11/6/2025 (Estimated)Latest MYGN, QDEL, HSKA, LNTH, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NTLAIntellia Therapeutics-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/5/2025Q2 2025QDELQuidelOrtho$0.0122$0.12+$0.1078-$3.77$612.36 million$613.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSKAHeskaN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSKAHeska0.235.644.12LNTHLantheus0.494.294.07MYGNMyriad GeneticsN/A1.421.28NTLAIntellia TherapeuticsN/A5.195.19QDELQuidelOrtho0.741.120.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSKAHeska99.01%LNTHLantheus99.06%MYGNMyriad Genetics99.02%NTLAIntellia Therapeutics88.77%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipHSKAHeska12.30%LNTHLantheus1.50%MYGNMyriad Genetics2.40%NTLAIntellia Therapeutics3.10%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSKAHeska80810.91 million9.57 millionNot OptionableLNTHLantheus70067.99 million66.97 millionOptionableMYGNMyriad Genetics2,70093.04 million90.81 millionOptionableNTLAIntellia Therapeutics600107.35 million104.02 millionOptionableQDELQuidelOrtho6,60067.90 million67.36 millionOptionableMYGN, QDEL, HSKA, LNTH, and NTLA HeadlinesRecent News About These CompaniesStanley Capital Management LLC Has $12.07 Million Holdings in QuidelOrtho Corporation $QDELSeptember 14, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Buys New Shares in QuidelOrtho Corporation $QDELSeptember 14, 2025 | marketbeat.comRBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy RatingSeptember 10, 2025 | insidermonkey.comFocus Partners Advisor Solutions LLC Invests $380,000 in QuidelOrtho Corporation $QDELSeptember 8, 2025 | marketbeat.comQuidelOrtho Corporation (NASDAQ:QDEL) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 8, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Stock Holdings Raised by AQR Capital Management LLCSeptember 7, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Shares Sold by Magnetar Financial LLCSeptember 5, 2025 | marketbeat.comQUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 4, 2025 | globenewswire.com67,619 Shares in QuidelOrtho Corporation $QDEL Purchased by Birchview Capital LPSeptember 4, 2025 | marketbeat.comHBK Investments L P Has $16.88 Million Stock Holdings in QuidelOrtho Corporation $QDELSeptember 3, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Holdings Increased by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.comIeq Capital LLC Increases Holdings in QuidelOrtho Corporation $QDELAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Has $1.42 Million Holdings in QuidelOrtho Corporation $QDELAugust 30, 2025 | marketbeat.comQuidelOrtho to Participate in the Baird 2025 Global Healthcare ConferenceAugust 28, 2025 | prnewswire.comJump Financial LLC Boosts Stake in QuidelOrtho Corporation $QDELAugust 28, 2025 | marketbeat.com221,658 Shares in QuidelOrtho Corporation $QDEL Acquired by Nuveen LLCAugust 27, 2025 | marketbeat.comQuidelOrtho Completes Major Debt Refinancing TransactionAugust 23, 2025 | theglobeandmail.comT. Rowe Price Investment Management Inc. Has $400.31 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 23, 2025 | marketbeat.comQuidelOrtho Corporation: QuidelOrtho Completes Debt RefinancingAugust 22, 2025 | finanznachrichten.deAmerican Century Companies Inc. Increases Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $28.99 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYGN, QDEL, HSKA, LNTH, and NTLA Company DescriptionsHeska NASDAQ:HSKAHeska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.Lantheus NASDAQ:LNTH$50.41 -1.15 (-2.23%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$51.52 +1.11 (+2.19%) As of 09/19/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Myriad Genetics NASDAQ:MYGN$7.77 +0.09 (+1.17%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$7.73 -0.04 (-0.57%) As of 09/19/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Intellia Therapeutics NASDAQ:NTLA$15.59 -0.52 (-3.23%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$15.63 +0.04 (+0.26%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.QuidelOrtho NASDAQ:QDEL$28.78 -0.96 (-3.23%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$28.78 0.00 (0.00%) As of 09/19/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
